Menopause finally gets a seat at the table

In October 2026, the U.S. Senate held its first hearing dedicated entirely to menopause. It felt overdue – not just because half the population will walk through it, but because the conversation has been muted for generations.

Senators Kirsten Gillibrand (D‑NY) and Rick Scott (R‑FL) invited a handful of doctors, researchers and advocates to testify. What emerged was a litany of shortcomings: too few specialists trained in menopausal care, insurance plans that barely acknowledge the condition, and a startling lack of federal funding for research. The senators even asked the Government Accountability Office to map out exactly where the money – and the knowledge – are missing.

Menopause is a natural, hormone‑driven transition that marks the end of fertility. For many women it brings hot flashes, night sweats, sleep disruption, mood swings, urinary urgency, brain fog, weight changes and headaches. Left untreated, these symptoms can upend daily life, strain families and even affect workplace performance.

Yet despite affecting roughly 50 % of U.S. adults, menopause has been treated like a taboo. It isn’t taught with the same rigor as childbirth. A survey of OB‑GYN residency programs found only about one‑third include a formal menopause curriculum. While the Accreditation Council for Graduate Medical Education mandates a minimum of 360 logged deliveries for OB‑GYN trainees, there is no comparable requirement for learning how to manage the hormonal shift that follows.

Most women first notice perimenopausal changes during routine primary‑care visits. Unfortunately, many internists admit they feel under‑prepared. Lack of training consistently shows up as the top barrier to quality care – a pattern that repeats worldwide.

Beyond the clinic, the silence seeps into the office. Employers readily roll out policies for pregnancy or disability, but menopause is often invisible on the benefits list. In the U.S., that omission can cost businesses dearly; a recent analysis put the annual economic impact at nearly $27 billion, driven by lost productivity and higher turnover.

The United Kingdom offers a different model. Companies with more than 250 employees must publish an annual Menopause Action Plan, a legal step meant to foster equitable, productive workplaces. The U.S. could learn a thing or two from that approach.

Complications multiply for women with a cancer history. Hormone‑replacement therapy (HRT) can soothe the worst symptoms, yet it’s usually off‑limits for breast‑cancer survivors because of recurrence risk. With one in eight American women facing a breast‑cancer diagnosis, the gap feels especially unfair.

Good news: the medical community is finally listening. The American College of Obstetricians and Gynecologists (ACOG) recently refreshed its menopause guidelines – the first major update in 12 years – offering clinicians clearer, evidence‑based pathways.

Public awareness is picking up, too. Comedian Amy Schumer fronted Midi Health’s “Midlife Back in Session” campaign, using humor to break the silence and remind women that it’s okay to talk about hot flashes in the break room.

All of this points to a simple truth: women deserve care grounded in science, not guesswork, and workplaces deserve policies that keep talent thriving. The Senate hearing is a start, but real change will need sustained funding, better training standards and a cultural shift that makes menopause as normal a topic as pregnancy.